The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021 Review


Authors: Ascierto, P. A.; Warner, A. B.; Blank, C.; Caracò, C.; Demaria, S.; Gershenwald, J. E.; Khushalani, N. I.; Long, G. V.; Luke, J. J.; Mehnert, J. M.; Robert, C.; Rutkowski, P.; Tawbi, H. A.; Osman, I.; Puzanov, I.
Review Title: The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021
Abstract: The Great Debate session at the 2021 Melanoma Bridge virtual congress (December 2–4) featured counterpoint views from experts on seven important issues in melanoma. The debates considered the use of adoptive cell therapy versus use of bispecific antibodies, mitogen-activated protein kinase (MAPK) inhibitors versus immunotherapy in the adjuvant setting, whether the use of corticosteroids for the management of side effects have an impact on outcomes, the choice of programmed death (PD)-1 combination therapy with cytotoxic T-lymphocyte-associated antigen (CTLA)-4 or lymphocyte-activation gene (LAG)-3, whether radiation is needed for brain metastases, when lymphadenectomy should be integrated into the treatment plan and then the last debate, telemedicine versus face-to-face. As with previous Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their respective personal view. Audiences voted both before and after each debate. © 2022, The Author(s).
Keywords: genetics; multimodality cancer therapy; combined modality therapy; staging; lymph node dissection; lymph node excision; lymphadenectomy; melanoma; protein kinase inhibitor; protein kinase inhibitors; immunotherapy; surgery; targeted therapy; cytotoxic t lymphocyte antigen 4; neoadjuvant; adjuvant; anti-ctla-4; mek inhibitor; braf inhibitor; ctla-4 antigen; humans; human; anti-pd-1
Journal Title: Journal of Translational Medicine
Volume: 20
ISSN: 1479-5876
Publisher: Biomed Central Ltd  
Date Published: 2022-05-10
Start Page: 200
Language: English
DOI: 10.1186/s12967-022-03406-7
PUBMED: 35538491
PROVIDER: scopus
PMCID: PMC9087170
DOI/URL:
Notes: Article -- Export Date: 1 June 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors